AM-Pharma
develops human alkaline phosphatase therapeutics for the treatment of acute kidney injury... Read moreAM-Pharma
develops human alkaline phosphatase therapeutics for the treatment of acute kidney injury... Read more
News
Oct 02, 2025
StreetInsider
Press Release: AM-Pharma : AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
Jan 16, 2024
Business Wire
Press Release: AM-Pharma : AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage
Oct 12, 2023
Pharmabiz
AM-Pharma: AMPharma reports positive data from phase 1b trial evaluating Ilofotase Alfa in hypophosphatasia patients
Mar 09, 2023
FinanzNachrichten
AM-Pharma: AM-Pharma to Present Data From Phase 3 REVIVAL Study at Upcoming Scientific Conferences
Oct 20, 2022
FinanzNachrichten
AM-Pharma: AM-Pharma B.V.: AM-Pharma Provides Business Update and Outcome of Pre-planned Interim Futility Analysis of Phase 3 REVIVAL Study
Oct 20, 2022
Endpoints News
AM-Pharma: AM-Pharma flies white flag on PhIII battle, but they aren't giving up on their kidney drug
Jul 05, 2022
Easy Tip
AM-Pharma: AM-Pharma Publicizes Publication of In Vivo Acute Kidney Damage Examine Demonstrating Ilofotase Alfa's Twin Protecting Mechanism
Jun 06, 2022
FinanzNachrichten
AM-Pharma: AM-Pharma B.V.: AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference
Apr 25, 2022
FirstWord Pharma
AM-Pharma: 400 Patients Have Been Enrolled in AM-Pharma's Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury
Mar 22, 2022
FinanzNachrichten
AM-Pharma: AM-Pharma B.V.: AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect
AM-Pharma Competitors
1
2
3
4
5
6
7
8
9
10